Brief: Daré Bioscience Announces Positive Topline Pharmacokinetic And Exploratory Efficacy Results From The Dare-Pdm1 Phase 1 Clinical Study
20/12/2023 13:09
Dec 20 (Reuters) - Dare Bioscience Inc DARE.O :
* DARÉ BIOSCIENCE ANNOUNCES POSITIVE TOPLINE
PHARMACOKINETIC AND
EXPLORATORY EFFICACY RESULTS FROM THE DARE-PDM1 PHASE 1 CLINICAL
STUDY
* DARE BIOSCIENCE: PENDING PLASMA PK DATA, TOPLINE RESULTS
SUPPORT
CONTINUED CLINICAL DEVELOPMENT OF DARE-PDM1 FOR PRIMARY
DYSMENORRHEA
Source text for Eikon: ID:nGNX1vDTMq
Further company coverage: DARE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dare Bioscience
See all newsBrief: Dare Bioscience - Files For Resale Of Up To 8,934,345 Shares Of Common Stock - SEC Filing
Brief: Daré Bioscience CEO Sabrina Martucci Johnson Named To Forbes 2026 “50 Over 50 Innovation” List
NASDAQ RESUMED AT 12:50 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:45 PM
Dare Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary